文献速递肿瘤 PET/CT放射性药物与辐射防护

[18F]AlF-NOTA-FAPI-04:FAP靶向特异性、生物分布及多种癌症的PET/CT显像

[18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-03-09

本先导研究开发了新型示踪剂[18F]AlF-NOTA-FAPI-04,在U87细胞和荷瘤小鼠中验证FAPI-04对FAP的结合特异性,并在28例8种癌症患者中行PET/CT显像。结果显示示踪剂肿瘤摄取高、体内清除快、图像对比度高、正常组织辐射暴露可忽略;7例晚期肺癌患者双示踪显像中该示踪剂检出44个转移灶,[18F]FDG检出37个。

要点

  • 体外与体内实验均显示FAPI-04对FAP具有高结合特异性。
  • 28例8种癌症患者中,[18F]AlF-NOTA-FAPI-04 PET/CT图像对比度高,正常组织辐射暴露可忽略。
  • 晚期肺癌患者中,[18F]AlF-NOTA-FAPI-04 PET/CT检出44个转移灶,[18F]FDG PET/CT检出37个。

核心结论

  • [18F]AlF-NOTA-FAPI-04作为FAP显像示踪剂具有高特异性,可实现肿瘤快速高对比度显像。
  • [18F]AlF-NOTA-FAPI-04在晚期肺癌患者中识别转移灶的能力优于[18F]FDG,可能有助于肿瘤分期。

研究设计与样本

  • 本先导研究在U87细胞中验证荧光标记FAPI-04变体对FAP的体外结合特异性。
  • 在荷瘤小鼠模型中用小动物PET/CT进行体内显像、竞争和动态扫描分析,评估[18F]AlF-NOTA-FAPI-04显像。
  • 对患者不同种类癌症行[18F]AlF-NOTA-FAPI-04 PET/CT显像分析其应用。
  • 共28例患者纳入PET/CT显像,涵盖8种不同类型癌症。

主要发现

  • 体外和体内结果均显示FAPI-04对FAP具有高结合特异性。
  • 荷瘤小鼠模型和癌症患者中均观察到示踪剂肿瘤内高摄取和体内快速清除。
  • 28例8种癌症患者的[18F]AlF-NOTA-FAPI-04 PET/CT图像对比度高,正常组织辐射暴露可忽略。
  • 28例中5例在静脉注射[18F]AlF-NOTA-FAPI-04后1小时、2小时和4小时行PET/CT扫描。
  • 7例晚期肺癌患者行双示踪显像,[18F]AlF-NOTA-FAPI-04 PET/CT检出44个转移灶,[18F]FDG PET/CT检出37个转移灶。

关键数值与推荐

  • [18F]AlF-NOTA-FAPI-04 PET/CT在28例8种癌症患者中显示高对比度图像和可忽略的正常组织辐射暴露。
  • 7例晚期肺癌患者中,[18F]AlF-NOTA-FAPI-04 PET/CT检出44个转移灶,[18F]FDG PET/CT检出37个转移灶。
  • 全部转移灶中80.0%被两种示踪剂共同识别,17.8%仅被[18F]AlF-NOTA-FAPI-04识别,2.2%仅被[18F]FDG识别。

临床怎么用

  • 作者认为[18F]AlF-NOTA-FAPI-04可能有助于晚期肺癌患者的肿瘤分期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this pilot study, we developed a new tracer, [18F]AlF-labeled FAPI-04 chelated with NOTA, denoted as [18F]AlF-NOTA-FAPI-04, and tested the specificity, biodistribution, and clinical application for PET/computed tomography (CT) imaging of various types of cancers in patients. METHODS: In vitro binding specificity of FAPI-04 to FAP was verified in U87 cells confocal of a fluorescence-labeled variant. In vivo imaging, competition, and dynamic scanning analyses were conducted to evaluate [18F]AlF-NOTA-FAPI-04 imaging in xenograft mouse model using small-animal PET/CT. The application of [18F]AlF-NOTA-FAPI-04 was analyzed by imaging different types of cancers in patients. RESULTS: Both in vitro and in vivo results showed high binding specificity of FAPI-04 to FAP. High intratumoral uptake and fast body clearance of the tracer were observed in the xenograft mouse model and cancer patients. High-contrast images and negligible radiation exposure to normal tissue were observed on [18F]AlF-NOTA-FAPI-04 PET/CT in 28 patients with 8 different types of cancers. Five of 28 patients underwent PET/CT scanning at 1 h, 2 h, and 4 h after intravenous injection of [18F]AlF-NOTA-FAPI-04. Seven patients with advanced lung cancer underwent dual-tracer imaging, and 44 and 37 metastatic lesions were detected by [18F]AlF-NOTA-FAPI-04 PET/CT and [18F]F-FDG PET/CT, respectively. Overall, 80.0% of metastatic lesions was identified by both [18F]AlF-NOTA-FAPI-04 and 18F-FDG, 17.8% by [18F]AlF-NOTA-FAPI-04 PET/CT only, and 2.2% by [18F]FDG PET/CT only. CONCLUSION: [18F]AlF-NOTA-FAPI-04 offers high specificity as a tracer for FAP imaging and allows fast imaging with high contrast in tumors. [18F]AlF-NOTA-FAPI-04 is better at identifying metastatic lesions in patients with advanced lung cancer than [18F]FDG, and its use may facilitate tumor staging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wei Y, Zheng J, Ma L, et al. [18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022. PMID: 35262766. doi:10.1007/s00259-022-05758-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。